AlphaQuest LLC Acquires 17,289 Shares of Amphastar Pharmaceuticals, Inc. $AMPH

AlphaQuest LLC lifted its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 149.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,882 shares of the company’s stock after purchasing an additional 17,289 shares during the period. AlphaQuest LLC owned 0.06% of Amphastar Pharmaceuticals worth $663,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in AMPH. GAMMA Investing LLC boosted its position in shares of Amphastar Pharmaceuticals by 46.6% during the 1st quarter. GAMMA Investing LLC now owns 1,333 shares of the company’s stock valued at $39,000 after purchasing an additional 424 shares in the last quarter. Cambridge Investment Research Advisors Inc. boosted its holdings in Amphastar Pharmaceuticals by 14.0% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 13,790 shares of the company’s stock worth $400,000 after acquiring an additional 1,694 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in Amphastar Pharmaceuticals by 9.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 15,326 shares of the company’s stock worth $434,000 after acquiring an additional 1,262 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in Amphastar Pharmaceuticals by 2.2% in the first quarter. Principal Financial Group Inc. now owns 212,647 shares of the company’s stock worth $6,165,000 after acquiring an additional 4,669 shares in the last quarter. Finally, Significant Wealth Partners LLC boosted its holdings in Amphastar Pharmaceuticals by 43.2% in the first quarter. Significant Wealth Partners LLC now owns 10,215 shares of the company’s stock worth $296,000 after acquiring an additional 3,080 shares in the last quarter. Institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Stock Performance

NASDAQ:AMPH opened at $24.04 on Tuesday. The company has a debt-to-equity ratio of 0.80, a current ratio of 3.29 and a quick ratio of 2.21. The business has a fifty day simple moving average of $27.21 and a two-hundred day simple moving average of $25.21. Amphastar Pharmaceuticals, Inc. has a 1 year low of $20.39 and a 1 year high of $53.96. The company has a market capitalization of $1.12 billion, a P/E ratio of 9.00 and a beta of 0.75.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Weiss Ratings reiterated a “hold (c-)” rating on shares of Amphastar Pharmaceuticals in a report on Wednesday, October 8th. Needham & Company LLC reissued a “buy” rating and issued a $36.00 price objective on shares of Amphastar Pharmaceuticals in a research note on Wednesday, October 22nd. Piper Sandler lowered their price objective on Amphastar Pharmaceuticals from $30.00 to $25.00 and set a “neutral” rating for the company in a research note on Friday, August 8th. Zacks Research raised Amphastar Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 16th. Finally, Bank of America increased their price objective on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 26th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $31.60.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.